scholarly journals THE INFLUENCE OF PERIOPERATIVE ALLOGENEIC BLOOD TRANSFUSION ON SYSTEMIC INDUCTION OF TUMOR GROWTH FACTORS IN THE EARLY POSTOPERATIVE PERIOD IN PATIENTS WITH COLORECTAL CANCER

2003 ◽  
Vol 64 (11) ◽  
pp. 2659-2664 ◽  
Author(s):  
Chikao MIKI ◽  
Yasuhiro INOUE ◽  
Toshimitsu ARAKI ◽  
Tsuyoshi HATADA ◽  
Kouji TANAKA ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Growth Factors ◽  
Blood Transfusion ◽  
Tumor Growth ◽  
Postoperative Period ◽  
Early Postoperative Period ◽  
Allogeneic Blood Transfusion ◽  
Allogeneic Blood ◽  
Systemic Induction

scholarly journals A cohort investigation of anaemia, treatment and the use of allogeneic blood transfusion in colorectal cancer surgery

2016 ◽  
Vol 6 ◽  
pp. 6-11 ◽  
Author(s):  
Barrie D. Keeler ◽  
Amitabh Mishra ◽  
Christiana L. Stavrou ◽  
Sophia Beeby ◽  
J. Alastair Simpson ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Blood Transfusion ◽  
Cancer Surgery ◽  
Allogeneic Blood Transfusion ◽  
Allogeneic Blood ◽  
Colorectal Cancer Surgery

Allogeneic blood transfusion in patients in Dukes B stage of colorectal cancer

2010 ◽  
Vol 28 (1) ◽  
pp. 170-174 ◽  
Author(s):  
Darko Zdravkovic ◽  
Dragoljub Bilanovic ◽  
Tomislav Randjelovic ◽  
Miroslav Granic ◽  
Blagoje Djukanovic ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Blood Transfusion ◽  
Allogeneic Blood Transfusion ◽  
Allogeneic Blood

scholarly journals Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells [see comments]

Blood ◽  
1993 ◽  
Vol 81 (7) ◽  
pp. 1880-1882
Author(s):  
MA Blajchman ◽  
L Bardossy ◽  
R Carmen ◽  
A Sastry ◽  
DP Singal
Keyword(s):  
Blood Transfusion ◽  
Tumor Growth ◽  
Inbred Mice ◽  
Allogeneic Blood Transfusion ◽  
Allogeneic Blood ◽  
Nodule Formation ◽  
Blood Transfusions ◽  
Spleen Cells ◽  
Promoting Effect ◽  
Growth Promoting

Allogeneic blood transfusions have been reported to induce immunomodulation in recipients of blood products. While the mechanism(s) of this immunomodulatory effect is unknown, it has been suggested that this effect of allogeneic blood transfusions could adversely affect patients with a malignant disorder. These concerns have been supported by a number of nonrandomized, mainly retrospective, clinical studies which indicate that allogeneic blood transfusions can adversely affect prognosis following the surgical treatment of oncology patients. Recently, we have shown that allogeneic blood transfusions enhance primary tumor growth and increase metastatic pulmonary nodule formation in inbred mice. The tumor growth-promoting activity of allogeneic blood transfusions was studied also using outbred rabbits. In this present study, we demonstrate that the tumor growth-promoting effect of allogeneic blood transfusions is mediated by donor leukocytes and that this effect can be abolished by their removal before transfusion. We show also that the allogeneic blood transfusion tumor growth-promoting effect can be passively transferred to naive animals (both mice and rabbits) using spleen cells from allogeneically transfused animals. In these experiments, numbers of metastatic pulmonary nodules were significantly increased in both mice and rabbits that had received spleen cells from allogeneically transfused animals compared with those that had received spleen cells from syngeneically transfused animals, or from animals that had been transfused with leukodepleted allogeneic blood.

scholarly journals Allogeneic blood transfusion-induced enhancement of tumor growth: two animal models showing amelioration by leukodepletion and passive transfer using spleen cells [see comments]

Blood ◽  
1993 ◽  
Vol 81 (7) ◽  
pp. 1880-1882 ◽  
Author(s):  
MA Blajchman ◽  
L Bardossy ◽  
R Carmen ◽  
A Sastry ◽  
DP Singal
Keyword(s):  
Blood Transfusion ◽  
Tumor Growth ◽  
Inbred Mice ◽  
Allogeneic Blood Transfusion ◽  
Allogeneic Blood ◽  
Nodule Formation ◽  
Blood Transfusions ◽  
Spleen Cells ◽  
Promoting Effect ◽  
Growth Promoting

Abstract Allogeneic blood transfusions have been reported to induce immunomodulation in recipients of blood products. While the mechanism(s) of this immunomodulatory effect is unknown, it has been suggested that this effect of allogeneic blood transfusions could adversely affect patients with a malignant disorder. These concerns have been supported by a number of nonrandomized, mainly retrospective, clinical studies which indicate that allogeneic blood transfusions can adversely affect prognosis following the surgical treatment of oncology patients. Recently, we have shown that allogeneic blood transfusions enhance primary tumor growth and increase metastatic pulmonary nodule formation in inbred mice. The tumor growth-promoting activity of allogeneic blood transfusions was studied also using outbred rabbits. In this present study, we demonstrate that the tumor growth-promoting effect of allogeneic blood transfusions is mediated by donor leukocytes and that this effect can be abolished by their removal before transfusion. We show also that the allogeneic blood transfusion tumor growth-promoting effect can be passively transferred to naive animals (both mice and rabbits) using spleen cells from allogeneically transfused animals. In these experiments, numbers of metastatic pulmonary nodules were significantly increased in both mice and rabbits that had received spleen cells from allogeneically transfused animals compared with those that had received spleen cells from syngeneically transfused animals, or from animals that had been transfused with leukodepleted allogeneic blood.

Blood transfusion-modulated tumor recurrence: first results of a randomized study of autologous versus allogeneic blood transfusion in colorectal cancer surgery.

1994 ◽  
Vol 12 (9) ◽  
pp. 1859-1867 ◽  
Author(s):  
M M Heiss ◽  
W Mempel ◽  
C Delanoff ◽  
K W Jauch ◽  
C Gabka ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Relative Risk ◽  
Blood Transfusion ◽  
Blood Group ◽  
Tumor Recurrence ◽  
Autologous Blood ◽  
Randomized Study ◽  
Allogeneic Blood Transfusion ◽  
Allogeneic Blood ◽  
Blood Transfusions

PURPOSE Allogeneic blood transfusions have reportedly been associated with a poor prognosis in patients with curatively resected cancer. To control for immunosuppression induced by a speculatively causal allogeneic blood transfusion, we designed a randomized study in which the control group received autologous blood transfusions not related to any condition of immunosuppression. PATIENTS AND METHODS One hundred twenty patients with potentially curative resectable colorectal cancer and the capability to predeposit autologous blood were randomly selected to receive either standard allogeneic blood transfusion or predeposited autologous blood. RESULTS In curatively resected cancer patients, the number who needed allogeneic blood transfusions was reduced from 60% in the allogeneic blood group to 33% in the autologous blood group (P = .009). After a median follow-up duration of 22 months (range, 8 to 48) tumor recurrence was observed in 28.9% of the allogeneic blood group and 16.7% of the autologous blood group. Life-table analysis established a tendency toward a shorter tumor-free survival for the allogeneic blood group (log-rank P = .11). The problem with this analysis was the strong association of allogeneic blood transfusions with tumor recurrence, which interfered in 33% of patients in the autologous blood group who required additional allogeneic blood transfusions. Multivariate analysis of established risk factors for tumor recurrence and surgery-related variables reflecting potential immunosuppressive conditions showed that only pT stage (relative risk, 6.61; 95% confidence interval [CI], 1.82 to 23.99; P = .004), pN stage (relative risk, 8.39; 95% CI, 3.15 to 22.33; P < .001), and the need for allogeneic blood (relative risk, 6.18; 95% CI, 2.20 to 17.37; P < .001) were independent predictors of tumor recurrence. Subgroup analysis of patients who received a transfusion of < or = 2 U blood found a significantly higher risk of tumor recurrence in the allogeneic blood group (relative risk, 5.16; 95% CI, 1.13 to 23.62; P = .034), which was reduced to borderline significance (relative risk, 3.54; 95% CI, 0.76 to 16.51; P = .107) by adjustment for tumor (T) and node (N) stage. CONCLUSION As indicated by these first results, the blood transfusion modality has a significant effect on tumor recurrence after surgical treatment of colorectal cancer. A change in the practice of blood transfusion might thus potentially surpass the impact of any recent adjuvant treatment strategies.

Sign in / Sign up

Export Citation Format

Share Document